Supernus Pharmaceuticals Inc (SUPN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012206
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; and Trokendi XR (topiramate), an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc (SUPN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Supernus Pharma Secures US$15 Million In Venture Financing 10
Supernus Pharma Raises US$15 Million In Venture Financing 11
Private Equity 12
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 12
Licensing Agreements 13
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 13
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 14
Equity Offering 15
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 15
Supernus Pharma Completes IPO For USD52.3 Million 17
Debt Offering 19
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 19
Acquisition 21
Supernus Pharma Sells TCD Royalty Sub For US$27 Million 21
Supernus Pharmaceuticals Inc – Key Competitors 22
Supernus Pharmaceuticals Inc – Key Employees 23
Supernus Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 06, 2017: Supernus Announces Third Quarter 2017 Financial Results 25
Aug 02, 2017: Supernus Announces Record Second Quarter 2017 Financial Results 27
May 09, 2017: Supernus Announces First Quarter 2017 Financial Results 29
Feb 28, 2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results 31
Aug 02, 2016: Supernus Announced Second Quarter 2016 Financial Results 33
Aug 02, 2016: Supernus Announces Second Quarter 2016 Financial Results 35
May 03, 2016: Supernus Announces First Quarter 2016 Financial Results 37
Mar 02, 2016: Supernus Announces Record Fourth Quarter and Full Year 2015 Financial Results 39
Corporate Communications 41
Aug 12, 2016: Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman 41
Other Significant Developments 42
Nov 14, 2016: Supernus Provides Business Update 42
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Supernus Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Supernus Pharma Secures US$15 Million In Venture Financing 10
Supernus Pharma Raises US$15 Million In Venture Financing 11
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 12
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 13
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 14
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 15
Supernus Pharma Completes IPO For USD52.3 Million 17
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 19
Supernus Pharma Sells TCD Royalty Sub For US$27 Million 21
Supernus Pharmaceuticals Inc, Key Competitors 22
Supernus Pharmaceuticals Inc, Key Employees 23
Supernus Pharmaceuticals Inc, Subsidiaries 24

★海外企業調査レポート[Supernus Pharmaceuticals Inc (SUPN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gastar Exploration Inc (GST):石油・ガス:M&Aディール及び事業提携情報
    Summary Gastar Exploration Inc (Gastar), formerly Gastar Exploration Ltd, is an energy company that offers exploration and development programs. The company explores, develops and produces natural gas, oil, and natural gas liquids. Its business activities include acquisition, identification, and exp …
  • Trovagene Inc (TROV):医療機器:M&Aディール及び事業提携情報
    Summary Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1 (PLK1) inhibitor that helps treat solid tumor cancers and multiple hematologic malignancie …
  • Michigan Public Power Agency:企業の発電所・SWOT分析2018
    Michigan Public Power Agency - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Euticals SpA-製薬・医療分野:企業M&A・提携分析
    Summary Euticals SpA (Euticals) is a chemical company that develops and supplies active pharmaceutical ingredients, fine chemicals and contract manufacturing. The company possess technologies and capabilities in the domains of fermentation and enzymatic chemistry; boronic acids, biaryls, grignards a …
  • Godrej Consumer Products Limited:企業の戦略・SWOT・財務情報
    Godrej Consumer Products Limited - Strategy, SWOT and Corporate Finance Report Summary Godrej Consumer Products Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Holland Board of Public Works:企業の戦略的SWOT分析
    Holland Board of Public Works - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • ACUTRONIC USA, Inc.:企業の戦略・SWOT・財務情報
    ACUTRONIC USA, Inc. - Strategy, SWOT and Corporate Finance Report Summary ACUTRONIC USA, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Wilbur-Ellis Company:企業の戦略・SWOT・財務情報
    Wilbur-Ellis Company - Strategy, SWOT and Corporate Finance Report Summary Wilbur-Ellis Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Technical Olympic SA:企業の戦略・SWOT・財務情報
    Technical Olympic SA - Strategy, SWOT and Corporate Finance Report Summary Technical Olympic SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • BaroFold Inc-製薬・医療分野:企業M&A・提携分析
    Summary BaroFold Inc (BaroFold) is a biotechnology company that provides protein refolding services. The company offers services such as research study services, optimization study services, and process implementation services. Its optimization study services include confirm analytical services, res …
  • Novelion Therapeutics Inc (NVLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Novelion Therapeutics Inc (Novelion), formerly QLT Inc, is a biopharmaceutical company that focuses on the development and commercialization of products and solutions for the treatment of people living with rare diseases. The company has two marketed products - Lomitapide, a small molecule m …
  • Aldi Einkauf GmbH & Co oHG:戦略・SWOT・企業財務分析
    Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report Summary Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Tulip Diagnostics (P) Ltd-医療機器分野:企業M&A・提携分析
    Summary Tulip Diagnostics (P) Ltd (Tulip Diagnostics), a subsidiary of Tulip Group is a diagnostic company that manufactures and markets in vitro diagnostic reagents and kits for the medical markets. The company provides assay systems for immunohaematology, hematology, rheumatology, infectious disea …
  • VTB Bank:戦略・SWOT・企業財務分析
    VTB Bank - Strategy, SWOT and Corporate Finance Report Summary VTB Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Themis Bioscience GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Themis Bioscience GmbH (Themis Bioscience) is a biotechnology company that develops prophylactic vaccines for emerging tropical infections. The company develops emerging and specialist indications and vaccines from preclinical to late-stage clinical development phases. It develops novel vacc …
  • OncoResponse Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OncoResponse Inc (OncoResponse) focuses on the discovery, development and commercialization of therapeutic antibodies for the treatment of cancer. The company’s lead program includes ONCR-201, an anti-EMP2 fully-human monoclonal antibody, which is developed for female malignancies. It utiliz …
  • Banner Corp:企業の戦略・SWOT・財務情報
    Banner Corp - Strategy, SWOT and Corporate Finance Report Summary Banner Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Henry Ford Health System:企業の戦略的SWOT分析
    Henry Ford Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • UniCredit S.p.A:企業のM&A・事業提携・投資動向
    UniCredit S.p.A - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UniCredit S.p.A Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • China Construction Bank Corp:企業の戦略・SWOT・財務情報
    China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report Summary China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆